AzTrials
AzTrials

Periodontal Treatment, CytokinesNCT05535049

Non-surgical Periodontal Treatment and Periostin Levels

A study testing Non-surgical periodontal treatment in people with Periodontal Treatment, Cytokines, run by Mustafa Kemal University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Two different studies were planned from the recruited samples. The aim of these studies was to investigate the effect of non-surgical periodontal treatment on the inflammatory markers levels in serum and gingival crevicular fluid (GCF) in patients with periodontitis. Read more about this study

Who is it for?
Ages 24 to 58 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Treatment, Cytokines
What is being tested?
Non-surgical periodontal treatment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Dec 2019to 1 Nov 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 24 to 58 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • individuals who had never smoked;
  • individuals who had no history of periodontal treatment in the past 6 months;
  • individuals who had had no antibiotic therapy in the past 3 months;
  • individuals who had more than 18 teeth.

Who cannot join

  • individuals who were pregnant;
  • individuals were current or former smokers;
  • individuals who had any self-reported systemic condition or disease, which are confounding factors e.g. AIDS, rheumatoid arthritis, cardiovascular diseases, diabetes.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Mustafa Kemal University

    Hatay, 31000

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect of Non-surgical Periodontal Treatment on Serum and Gingival Crevicular Fluid Periostin Levels

Two different studies were planned from the recruited samples. The aim of these studies was to investigate the effect of non-surgical periodontal treatment on the inflammatory markers levels in serum and gingival crevicular fluid (GCF) in patients with periodontitis.

There were two groups consisting of individuals who had periodontitis and those who were healthy, with 24 individuals in each group.

Read more

Periostin levels were assessed at baseline, at the 24th h, 48th h, 14th day 1st month, 3rd month after non-surgical periodontal treatment in serum and GCF samples by the Elisa method in the first study. In parallel, interleukin 1 (IL)-beta and fibroblast growth factor levels were measured.

Progranulin levels were assessed at baseline, at the 24th h, 48th h, 14th day 1st month, 3rd month after non-surgical periodontal treatment in serum and GCF samples by the Luminex method in the second study. In parallel, vascular endothelial growth factor, IL-1 beta, tumor necrosis factor-alpha, and IL-10 levels were measured.

Read the detailed description

The First Study

The observational prospective study was designed to characterize periostin changes over time after non-surgical periodontal treatment in serum and GCF in the Department of Periodontology in the Faculty of Dentistry at Hatay Mustafa Kemal University, Hatay, Turkey. The study protocol was approved by the Ethics Committee for the Use of Human Subjects in Research of Hatay Mustafa Kemal University (Protocol No: 2019/118). The study was carried out in accordance with the tenets of the Declaration of Helsinki and conducted in CONSORT guidelines (Schulz, Altman, \& Moher, 2010). This study project was financially supported by Hatay Mustafa Kemal University Scientific Research Projects Coordinator (19M051).

Individuals were included in the study from December 2019 through August 2021. Written informed consent was obtained from each participant before the clinical periodontal examination.

Study Population

Forty-eight adult individuals were enrolled in the study. Participants were recruited into 2 sex matched groups with 24 participants in each: periodontally healthy (PH) and periodontitis (P) groups. In accordance with the demographic variables of the patients included in the P group, the patients in the PH groups were included.

Periodontal Parameters

Periodontal clinical parameters were recorded by a single calibrated examiner (k =0.95) (author AS). Intra-examiner agreement was determined for CAL. The intra-examiner reproducibility was determined through repeated examinations of 10 subjects with a one-hour interval. Clinical periodontal measurements were assessed using the following periodontal measurements for periodontal diagnosis in both groups and also at the 1st month, 3rd month after non-surgical periodontal treatment in the periodontitis group.

The measurements were performed using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA) and included probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI) (Silness \& Loe, 1964), gingival index (GI) (Loe \& Silness, 1963), and percentage bleeding on probing (BOP) (Ainamo \& Bay, 1975) at six sites per tooth (mesio-buccal, buccal, disto-buccal, mesio-lingual, lingual and disto-lingual) on each tooth.

Diagnosis of periodontal diseases and conditions was made according to the radiographic and clinical diagnostic criteria proposed by the 2017 World Workshop on Classification of Periodontal and Peri-implant Diseases and Conditions (Caton et al., 2018). Individuals with BOP < 10% without attachment loss and radiographic bone loss were considered to have periodontal health (Tonetti \& Sanz, 2019). The criteria for periodontitis included patients with CAL ≥ 5 mm in two or more interproximal sites and PPD ≥ 6 mm in one or more interproximal sites. Only stage III-IV (severe) periodontitis was included in the present study (Tonetti, Greenwell, \& Kornman, 2018).

Periodontal Intervention

Periodontitis patients were treated by one-stage full-mouth disinfection. Full-mouth disinfection included full-mouth scaling and root planning procedures within 24 h in two sessions. Each session was practiced for 60 min on two consecutive days. Subgingival irrigation and tongue brushing were made with 1% CHX gel for 1 min. Mouthwashes with 0.12% CHX were performed for 30 s at the beginning and at the end of each session and twice a day for 2 weeks (Quirynen et al., 1995).

Collection of GCF Samples

GCF samples were collected following 8 hours of night fasting and one week after clinical periodontal measurements at baseline in two groups and then at the the 24th h, 48th h, 14th day 1st month, 3rd month after non-surgical periodontal treatment (Akalin, Baltacioglu, Alver, \& Karabulut, 2007). The samples were collected from the teeth side with PPDs ≥6 mm, and BOP positive in patients with periodontitis. Six GCF samples were taken per participant. Samples were collected from a mesial and a distal site on each of three teeth (incisors, premolars, and molars). Saliva contamination was prevented by isolation with cotton rolls and gently air-drying the sampling area. Samples contaminated with saliva or blood were not included. Plaque was gently removed from the sampling area by the periodontal curette. The samples were collected within 30 seconds with standardized paper strips (Periopaper; Oraflow Inc., Plainview, NY) by the orifice method.(Rudin, Overdiek, \& Rateitschak, 1970) The volumes were measured on a pre-calibrated electronic gingival fluid measuring device (Oraflow Inc., Plainview, NY)|| (Chapple, Landini, Griffiths, Patel, \& Ward, 1999). The values of the electronic device were referenced to a standard curve and converted to an actual volume (µl). All of the Periopaper strips were pooled in plastic Eppendorf microcentrifuge tubes. They were stored at -80 °C until the biochemical analysis.

All samples were thawed and 375 μl of phosphate buffered saline (pH:7.00, 10 mM Na2PO4, 137 mM NaCl, and 2.7 mM KCl) was added into the eppendorf tubes containing the sample strips. Subsequently, samples were eluted for 30 minutes at room temperature and (Chapple et al., 1997) centrifuged at 11000×g for 15 min at 4 °C. The measurement of periostin, IL-1β, and FGF levels were assayed.

Collection of Serum Samples

Peripheral venous blood samples were taken from the patients. The serum was separated from the cells by centrifugation at 2000 rpm for 10 min, after which it was stored at -80°C, until the biochemical analysis was performed.

Laboratory Analyses

Periostin, IL-1β, and FGF levels were measured by the enzyme-linked immunosorbent assay (ELISA) using commercially available kits at 450 nm wavelength in ELISA Reader (Thermo Fisher Scientific Multiscan Go-Finland).

Measurement of periostin levels in GCF samples

Periostin levels were measured by ELABSCIENCE Human POSTN/OSF-2 (Kit Cat No: E-EL-H6113). The assay ranges for the periostin were 3.13-200 ng/ml; sensitivity, 1.88 ng/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

Measurement of IL-1β levels in GCF samples

IL-1β levels were measured by ELABSCIENCE Human IL-1β (Kit Cat No: E-EL-H0149). The assay ranges for the IL-1β were 7.81-500 pg/ml; sensitivity, 4.69 pg/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

Measurement of FGF levels in GCF samples

FGF levels were measured by ELABSCIENCE Human FGF21 (Kit Cat No: E-EL-H0074). The assay ranges for the FGF were 31.25-2000 pg/ml; sensitivity, 18.75 pg/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

The Second Study

The study aimed to evaluate the effect of non-surgical periodontal treatment on serum and gingival crevicular fluid progranulin levels.

3 paper strips and serum samples for each patient recruited from the same patients and same methods as back-up samples were transferred to King's College London Dental Institute, Periodontology Unit, Centre for Host-Microbiome Interactions, London, UK; after a material transfer agreement signed between Hatay Mustafa Kemal University, Hatay, Turkey and King's College London, London, UK in May 2022 for another study. T The study protocol was approved by the Ethics Committee for the Use of Human Subjects in Research of Hatay Mustafa Kemal University (Protocol No: 2022/90). The study was carried out in accordance with the tenets of the Declaration of Helsinki and conducted in the CONSORT guidelines (Schulz, Altman, \& Moher, 2010). This study project was financially supported by King's College London internal departmental funds.

GCF Samples Elution

50 μL of PBS/protease inhibitor cocktail (PBS with protease inhibitors 1X, Complete ULTRA tablets, Mini; EDTA-free) were added to a sterile microcentrifuge tube included 3 paper strips and centrifuged at 11000 rpm for 15 min at 4 C for GCF elutiation. This procedure was repeated two times and obtained a total volume of 100 μL. They were stored at -80 °C until the biochemical analysis.

Serum and GCF Samples Analyses

Luminex bead-based multiplex immunoassay (Luminex, R\&D systems, Minneapolis, MN) was used to carry out the analysis (in duplicate) of each sample. A custom-made 5-plex kit included inflammatory and regenerative markers: Progranulin (PGRN), VEGF, interleukin (IL)-1 beta, tumor necrosis factor-alpha (TNF-alfa), and IL-10.

Each 50-μL sample was resuspended in a dedicated well with a microparticle cocktail of antibodies covered with a foil plate sealer on magnetic beads and incubated for 2 h on a horizontal orbital microplate shaker. Following washes, the biotin antibody cocktail was added and incubated for 1 h as previously reported. After the washes, streptavidin-phycoerythrin (Streptavidin-PE) incubation was carried out for 30 min. Then, the samples were put into the Luminex MAGPIX analyzer (Luminex; R\&D systems) to read. The marker values were obtained as pg/mL.

Statistical Analysis

The normality of the distribution of continuous variables was tested by the Shapiro-Wilk test. Descriptive statistics were presented as mean and standard deviation (mean±sd) for parametric distributed variables and median (interquartile range) for the non-parametric distributed variables.

The chi-square test was used to analyze the associations between categorical variables. The Student t-test for normally distributed numerical variables and Mann Whitney u test for non-normally distributed numerical variables were performed to compare 2 independent groups for numerical data. Freidman test was performed for different time points with non-parametric variables. Dunn multiple comparison tests were performed for post hoc pairwise multiple comparison analyses.

Statistical analysis was performed with SPSS for Windows version 24.0 and P value <0.05 was accepted as statistically significant.

Being tested
Non-surgical periodontal treatment
Keywords
Periodontitis, Periostin, Periodontal treatment, Gingival crevicular fluid
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non-surgical periodontal treatmentProcedure or surgery

    Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.

Study groups in NCT05535049
Study groupRoleWhat they receive
Periodontally healthy groupNo intervention24 participants were included in this group.
Periodontitis groupActive comparator24 participants were included in this group.
Receives: Procedure: Non-surgical periodontal treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of Periostin levels in non-surgical periodontal treatment

    The effect of non-surgical periodontal treatment on serum and gingival crevicular fluid periostin levels

    Measured: 0-3 month

Secondary outcomes (1)
  1. Evaluation of IL-1B and FGF levels in non-surgical periodontal treatment

    The effect of non-surgical periodontal treatment on serum and gingival crevicular fluid cytokines levels

    Measured: 0-3 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2022
  2. Study start1 Dec 2019
  3. Primary completion1 Aug 2021
  4. Study completion1 Nov 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05535049
Sponsor's protocol ID
2019/118
Status last verified
Oct 2023
First submitted
6 Sep 2022
Last updated
11 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J. 1975 Dec;25(4):229-35.

    PubMed 1058834
  • Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, Mealey BL, Papapanou PN, Sanz M, Tonetti MS. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Periodontol. 2018 Jun;89 Suppl 1:S1-S8. doi: 10.1002/JPER.18-0157.

    PubMed 29926946
  • Chapple IL, Landini G, Griffiths GS, Patel NC, Ward RS. Calibration of the Periotron 8000 and 6000 by polynomial regression. J Periodontal Res. 1999 Feb;34(2):79-86. doi: 10.1111/j.1600-0765.1999.tb02226.x.

    PubMed 10207836
  • Chapple IL, Mason GI, Garner I, Matthews JB, Thorpe GH, Maxwell SR, Whitehead TP. Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. Ann Clin Biochem. 1997 Jul;34 ( Pt 4):412-21. doi: 10.1177/000456329703400413.

    PubMed 9247675
  • LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available.

    PubMed 14121956
  • Quirynen M, Bollen CM, Vandekerckhove BN, Dekeyser C, Papaioannou W, Eyssen H. Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations. J Dent Res. 1995 Aug;74(8):1459-67. doi: 10.1177/00220345950740080501.

    PubMed 7560400
  • Rudin HJ, Overdiek HF, Rateitschak KH. Correlation between sulcus fluid rate and clinical and histological inflammation of the marginal gingiva. Helv Odontol Acta. 1970 Apr;14(1):21-6. No abstract available.

    PubMed 5438796
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24.

    PubMed 20335313
  • SILNESS J, LOE H. PERIODONTAL DISEASE IN PREGNANCY. II. CORRELATION BETWEEN ORAL HYGIENE AND PERIODONTAL CONDTION. Acta Odontol Scand. 1964 Feb;22:121-35. doi: 10.3109/00016356408993968. No abstract available.

    PubMed 14158464
  • Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Clin Periodontol. 2018 Jun;45 Suppl 20:S149-S161. doi: 10.1111/jcpe.12945.

    PubMed 29926495
  • Tonetti MS, Sanz M. Implementation of the new classification of periodontal diseases: Decision-making algorithms for clinical practice and education. J Clin Periodontol. 2019 Apr;46(4):398-405. doi: 10.1111/jcpe.13104.

    PubMed 30883878
  • Yang N, Li Y, Wang G, Ding Y, Jin Y, Xu Y. Tumor necrosis factor-alpha suppresses adipogenic and osteogenic differentiation of human periodontal ligament stem cell by inhibiting miR-21/Spry1 functional axis. Differentiation. 2017 Sep-Oct;97:33-43. doi: 10.1016/j.diff.2017.08.004. Epub 2017 Sep 1.

    PubMed 28946056
  • Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000 Jul;48(7):999-1009. doi: 10.1177/002215540004800713.

    PubMed 10858277
  • Li X, Zuo Z, Chen Q, Li J, Tang W, Yang P. Progranulin is highly expressed in patients with chronic periodontitis and protects against experimental periodontitis in rats. J Periodontol. 2018 Dec;89(12):1418-1427. doi: 10.1002/JPER.18-0132. Epub 2018 Sep 11.

    PubMed 29999528
  • Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999 Jul;14(7):1239-49. doi: 10.1359/jbmr.1999.14.7.1239.

    PubMed 10404027

Questions about this trial

What is this clinical trial studying?

A study testing Non-surgical periodontal treatment in people with Periodontal Treatment, Cytokines, run by Mustafa Kemal University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of Periostin levels in non-surgical periodontal treatment (time frame: 0-3 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05535049, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in